Safety Review Committee (SRC) approves single ascending dose 4mg cohort in Phase 1 trial of PMC-403, preparing for multiple ascendi ...
A new statistical models shed light on why some patients can extend the dosing interval with Eylea (aflibercept) from 8 weeks ...
This Phase 1 trial targets patients with neovascular AMD ... for Phase 2 trials." Macular degeneration, a leading cause of blindness, results from aging-related damage to the retina, particularly ...
Neovascular age-related macular degeneration is responsible for the overwhelming majority of vision loss in age-related macular degeneration. Not too long ago, the disease was poorly controlled ...
The following is a summary of “Submacular hemorrhage rates following anti-vascular endothelial growth factor injections for ...
Nutritional supplements that contain curcumin -- a natural anti-inflammatory compound -- may protect the eyes from the ...
Patients with neovascular age-related macular degeneration diagnosed by a primary care clinician may be more likely to miss ...
Medpage Today on MSN6d
Potentially Large Cost Savings With Home-Based OCT for Neovascular AMDCHICAGO -- An artificial intelligence (AI)-based study of home monitoring for neovascular age-related macular degeneration ...
A recent study, published in the journal Nature looked into the six-month impact of switching to faricimab instead of ...
Opens in a new tab or window CHICAGO -- An artificial intelligence (AI)-based study of home monitoring for neovascular age-related macular degeneration (AMD) suggested a potential annual savings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback